German Federal Institute for Risk Assessment (BfR), Berlin, Germany.
Environ Health. 2024 Jun 4;23(1):52. doi: 10.1186/s12940-024-01092-0.
Risk assessment (RA) of microbial secondary metabolites (SM) is part of the EU approval process for microbial active substances (AS) used in plant protection products (PPP). As the number of potentially produced microbial SM may be high for a certain microbial strain and existing information on the metabolites often are low, data gaps are frequently identified during the RA. Often, RA cannot conclusively clarify the toxicological relevance of the individual substances. This work presents data and RA conclusions on four metabolites, Beauvericin, 2,3-deepoxy-2,3-didehydro-rhizoxin (DDR), Leucinostatin A and Swainsonin in detail as examples for the challenging process of RA. To overcome the problem of incomplete assessment reports, RA of microbial AS for PPP is in need of new approaches. In view of the Next Generation Risk Assessment (NGRA), the combination of literature data, omic-methods, in vitro and in silico methods combined in adverse outcome pathways (AOPs) can be used for an efficient and targeted identification and assessment of metabolites of concern (MoC).
风险评估(RA)是微生物活性物质(AS)用于植物保护产品(PPP)获得欧盟批准的过程的一部分。由于对于特定微生物菌株,可能会产生大量潜在的微生物次级代谢物(SM),而代谢物的现有信息通常较少,因此在 RA 过程中经常会发现数据空白。通常,RA 无法明确确定单个物质的毒理学相关性。本工作详细介绍了 beauvericin、2,3-去氧-2,3-二脱氢根皮素(DDR)、leucinostatin A 和 swainsonin 这四种代谢物的数据和 RA 结论,作为 RA 这一具有挑战性的过程的示例。为了克服评估报告不完整的问题,需要对 PPP 中的微生物 AS 的 RA 采用新方法。鉴于下一代风险评估(NGRA),可以将文献数据、组学方法、体外和计算方法结合在不良结局途径(AOP)中,用于有效和有针对性地识别和评估关注的代谢物(MoC)。